000 | 01964 a2200565 4500 | ||
---|---|---|---|
005 | 20250511182458.0 | ||
264 | 0 | _c19921026 | |
008 | 199210s 0 0 eng d | ||
022 | _a0007-1048 | ||
024 | 7 |
_a10.1111/j.1365-2141.1992.tb08244.x _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aMarks, D I | |
245 | 0 | 0 |
_aHLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. _h[electronic resource] |
260 |
_bBritish journal of haematology _cJul 1992 |
||
300 |
_a383-90 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdolescent |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aBone Marrow Transplantation _ximmunology |
650 | 0 | 4 | _aChild |
650 | 0 | 4 |
_aCyclosporine _xtherapeutic use |
650 | 0 | 4 |
_aDNA, Neoplasm _xgenetics |
650 | 0 | 4 | _aDrug Therapy, Combination |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aFusion Proteins, bcr-abl _xgenetics |
650 | 0 | 4 |
_aGraft vs Host Disease _ximmunology |
650 | 0 | 4 |
_aHLA Antigens _ximmunology |
650 | 0 | 4 |
_aHistocompatibility _ximmunology |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _ximmunology |
650 | 0 | 4 | _aMale |
650 | 0 | 4 |
_aMethotrexate _xtherapeutic use |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aPolymerase Chain Reaction |
650 | 0 | 4 | _aPrognosis |
650 | 0 | 4 |
_aRNA, Messenger _xanalysis |
650 | 0 | 4 | _aRecurrence |
650 | 0 | 4 |
_aTranscription, Genetic _xgenetics |
700 | 1 | _aHughes, T P | |
700 | 1 | _aSzydlo, R | |
700 | 1 | _aKelly, S | |
700 | 1 | _aCullis, J O | |
700 | 1 | _aSchwarer, A P | |
700 | 1 | _aMackinnon, S | |
700 | 1 | _aApperley, J | |
700 | 1 | _aBarrett, A J | |
700 | 1 | _aHows, J M | |
773 | 0 |
_tBritish journal of haematology _gvol. 81 _gno. 3 _gp. 383-90 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2141.1992.tb08244.x _zAvailable from publisher's website |
999 |
_c1396707 _d1396707 |